Sign in to view content

Primary Analysis Results of the Phase 3 Archway Trial of the Port Delivery System With Ranibizumab (PDS) for Patients With Neovascular AMD

Peter A. Campochiaro, MD

Video
Published 2020

Related

Episode 21: Eyes with PDR that were Lost to Followup after PRP or Anti-VEGF Treatment with Dr. Jason Hsu
Keyvan Koushan, MD, FRCSC
Member Podcasts
2018
Extended Q16W Dosing Potential for Faricimab in Neovascular Age-Related Macular Degeneration (nAMD): STAIRWAY Phase 2 Trial
Philip J. Ferrone, MD, FASRS
Annual Meeting Talks
2019
Randomized Trial of PRP vs Intravitreal Ranibizumab Plus Deferred PRP for Proliferative Diabetic Retinopathy
Andrew N. Antoszyk, MD FASRS
Updates from the Field
2016

Category: AMD-Neovascular

See more